tiprankstipranks
Trending News
More News >
Animalcare Group plc (GB:ANCR)
:ANCR

Animalcare (ANCR) AI Stock Analysis

Compare
4 Followers

Top Page

GB

Animalcare

(LSE:ANCR)

Rating:81Outperform
Price Target:
328.00p
▲(17.99%Upside)
Animalcare's strong financial performance, attractive valuation, and positive corporate events contribute significantly to its high stock score. Technical analysis supports the bullish outlook, with the company well-positioned for future growth despite minor concerns about rising liabilities.
Positive Factors
Acquisition Impact
The acquisition of Randlab represents a good price given the deal will boost top-line growth, be strongly accretive to margins, and drive double-digit earnings growth.
Market Positioning
Animalcare has positioned itself favorably in the resilient and growing veterinary pharma market via a balanced exposure to companion, production, and equine markets.
Valuation and Target Price
Analyst's target price for Animalcare increases to 350p, placing it at a premium to peers, which is warranted for a business accelerating top-line growth and driving margin expansion.
Negative Factors
Market Competition
With the stock currently trading at a slight discount to peers, there is an attractive entry point for investors.

Animalcare (ANCR) vs. iShares MSCI United Kingdom ETF (EWC)

Animalcare Business Overview & Revenue Model

Company DescriptionAnimalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in the wholesale and marketing of veterinary pharmaceuticals. The company serves customers in Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, other European countries, Asia, the Middle East, Africa, and internationally. Animalcare Group plc was incorporated in 1972 and is based in York, the United Kingdom.
How the Company Makes MoneyAnimalcare makes money through the sale of its diverse portfolio of veterinary products, which includes pharmaceuticals, vaccines, and equipment for both companion animals and livestock. The company's revenue streams are primarily driven by product sales to veterinary practices, wholesalers, and distributors across Europe. Animalcare also invests in R&D to develop new and innovative products, which can lead to new revenue opportunities. Strategic partnerships and collaborations with other companies in the veterinary sector further strengthen its market position and contribute to its earnings. The company's revenue is influenced by factors such as animal health trends, regulatory approvals, and the overall economic environment in the regions it operates.

Animalcare Financial Statement Overview

Summary
Animalcare shows overall financial strength with improved net profit margins and return on equity. The balance sheet is stable with a low debt-to-equity ratio, though rising liabilities warrant attention. Cash flow generation is consistent, supporting operational strategies despite slight revenue contraction.
Income Statement
75
Positive
Animalcare has demonstrated stable revenue with a slight decrease in 2024. The gross profit margin remains strong at around 45.9% in 2024, reflecting efficient production. The net profit margin has significantly improved from previous years, reaching 43.4% in 2024, due to increased net income influenced by effective cost management. However, the revenue growth rate is negative over the past year, indicating a potential challenge in expanding market share.
Balance Sheet
70
Positive
The balance sheet shows a healthy equity ratio of 71.3% in 2024, indicating strong financial stability. The debt-to-equity ratio is low at 0.20, reflecting minimal leverage and low financial risk. Return on equity improved drastically to 28.4% in 2024, demonstrating enhanced profitability. However, the increase in total liabilities over the years could pose future risks if not managed effectively.
Cash Flow
65
Positive
Animalcare's cash flow statements reveal consistent free cash flow generation, with a growth rate of 51.7% from 2023 to 2024, supporting financial flexibility. The operating cash flow to net income ratio is robust at 0.37, indicating good cash conversion. However, the free cash flow to net income ratio is slightly lower at 0.36, suggesting some inefficiencies in cash utilization relative to net income.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
74.23M74.35M71.62M74.02M70.49M
Gross Profit
34.06M43.35M40.66M39.42M36.56M
EBIT
4.50M4.41M3.24M1.99M2.59M
EBITDA
13.43M12.23M11.04M10.15M10.30M
Net Income Common Stockholders
32.22M1.20M1.97M-77.00K234.00K
Balance SheetCash, Cash Equivalents and Short-Term Investments
11.71M4.64M6.04M5.63M5.26M
Total Assets
158.81M106.79M118.24M110.00M124.44M
Total Debt
23.16M5.88M11.44M10.96M18.88M
Net Debt
11.45M1.23M5.40M5.33M13.62M
Total Liabilities
45.50M28.90M39.26M31.20M42.84M
Stockholders Equity
113.31M77.89M78.99M78.80M81.59M
Cash FlowFree Cash Flow
11.72M7.73M6.48M10.81M8.68M
Operating Cash Flow
11.93M10.28M9.43M14.02M11.12M
Investing Cash Flow
-34.85M-2.86M-3.12M-2.96M-2.91M
Financing Cash Flow
32.53M-8.95M-5.70M-10.96M-8.86M

Animalcare Technical Analysis

Technical Analysis Sentiment
Positive
Last Price278.00
Price Trends
50DMA
248.18
Positive
100DMA
239.88
Positive
200DMA
240.62
Positive
Market Momentum
MACD
11.93
Positive
RSI
55.33
Neutral
STOCH
19.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANCR, the sentiment is Positive. The current price of 278 is above the 20-day moving average (MA) of 277.35, above the 50-day MA of 248.18, and above the 200-day MA of 240.62, indicating a bullish trend. The MACD of 11.93 indicates Positive momentum. The RSI at 55.33 is Neutral, neither overbought nor oversold. The STOCH value of 19.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ANCR.

Animalcare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
£195.93M5.2733.70%1.41%-0.17%2591.96%
GBHIK
71
Outperform
£4.73B16.7715.79%2.69%5.83%83.35%
GBEAH
62
Neutral
£42.69M63.400.80%-4.37%
GBAPH
59
Neutral
$355.92M-5.04%-1.02%67.70%
GBBMK
59
Neutral
£178.70M
-16.14%-68.06%
54
Neutral
$5.41B3.27-45.10%3.29%16.81%0.02%
GBAGY
51
Neutral
£314.59M-369.20%4.50%74.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:ANCR
Animalcare
278.00
38.03
15.85%
GB:AGY
Allergy Therapeutics
7.25
2.00
38.10%
GB:APH
Alliance Pharma
64.70
31.85
96.96%
GB:BMK
Benchmark Holdings
23.80
-20.20
-45.91%
GB:EAH
Eco Animal Health
61.50
-68.50
-52.69%
GB:HIK
Hikma Pharmaceuticals
2,128.00
220.97
11.59%

Animalcare Corporate Events

M&A TransactionsBusiness Operations and Strategy
Animalcare Expands into Asia-Pacific with Strategic Stake in InVetro
Positive
Jun 13, 2025

Animalcare Group plc has acquired a 25% equity stake in InVetro Pty Ltd, an Australian-based Companion Animal health business, for A$3 million. This strategic investment is part of Animalcare’s geographic expansion strategy, aiming to establish a presence in the fast-growing Companion Animal health market in Australia and potentially other Asia-Pacific territories. The investment will enable InVetro to scale its commercial operations, expand its product portfolio, and develop new products. Animalcare’s long-term goal is to build a Companion Animal business in the region with revenues of A$20-25 million. The partnership provides Animalcare with immediate market access, leveraging InVetro’s local expertise and regulatory capabilities, and sets the stage for future collaboration and increased ownership.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Shareholder MeetingsDividendsBusiness Operations and Strategy
Animalcare Group plc Successfully Passes All Resolutions at 2025 AGM
Positive
Jun 10, 2025

Animalcare Group plc announced that all resolutions proposed at its 2025 Annual General Meeting were approved. The resolutions included the receipt of audited accounts, declaration of a final dividend, re-election of directors, and authorization for share allotment and purchase. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives and maintain its market presence.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Private Placements and Financing
Animalcare Group Announces New Share Issuance Under Incentive Plan
Neutral
May 30, 2025

Animalcare Group plc has announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 4,157 new ordinary shares. These shares will commence trading on AIM on 4 June 2025 and will be fully paid, ranking equally with existing shares. Following this issuance, the total number of shares with voting rights will be 68,989,072, providing a new denominator for shareholders to calculate their interests under the FCA’s rules.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Private Placements and FinancingRegulatory Filings and Compliance
Animalcare Group Announces New Share Issuance Following Option Exercise
Neutral
May 30, 2025

Animalcare Group plc, an international animal health business, announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 4,157 new ordinary shares. These shares will be admitted to trading on AIM on June 4, 2025, and will carry the same rights as existing shares, including voting rights. This issuance increases the total number of shares with voting rights to 68,989,072, impacting shareholder calculations under the FCA’s Disclosure and Transparency Rules.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Animalcare Group PLC Announces Change in Major Holdings
Neutral
May 23, 2025

Animalcare Group PLC has announced a change in its major holdings, with Harwood Capital LLP adjusting its voting rights in the company. The notification indicates that Harwood Capital LLP’s voting rights have decreased from 10.232840% to 9.929000%, reflecting a slight reduction in their stake. This adjustment in holdings could influence the company’s governance and decision-making processes, potentially impacting its strategic direction and stakeholder interests.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Shareholder MeetingsFinancial Disclosures
Animalcare Group Releases 2024 Annual Report and Announces 2025 AGM
Positive
May 16, 2025

Animalcare Group plc has published its 2024 Annual Report and Financial Statements, along with the Notice of its 2025 Annual General Meeting. The AGM is scheduled for 10 June 2024 in London. This release highlights the company’s commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

DividendsBusiness Operations and Strategy
Animalcare Group PLC Announces Corrected Dividend Timetable for 2024
Neutral
Apr 29, 2025

Animalcare Group PLC announced a correction to the dividend payment timetable for the year ended 31 December 2024. The Board proposes a final dividend of 3.0 pence per share, consistent with the previous year, pending shareholder approval at the Annual General Meeting on 10 June 2025. The dividend will be paid on 18 July 2025, with shares becoming ex-dividend on 19 June 2025. This announcement maintains the company’s commitment to returning value to shareholders, reflecting stability in its financial strategy.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Animalcare Group Reports Strong 2024 Results and Strategic Acquisition
Positive
Apr 29, 2025

Animalcare Group plc reported strong financial performance for the year ended December 2024, with revenues from continuing operations increasing by 4.9% to £74.2m. The company completed a transformational acquisition of Randlab, enhancing its position in the equine sector and expanding its reach into the Asia Pacific markets. The acquisition, along with the sale of non-core assets, strengthened the balance sheet and supported both organic and inorganic growth strategies. The Group’s strategic focus on R&D and product development, particularly in the novel VHH antibody program, positions it well for future growth. The company’s robust financial health and strategic acquisitions underscore its commitment to long-term growth and market expansion.

M&A TransactionsBusiness Operations and Strategy
Animalcare Group PLC Announces Change in Voting Rights Structure
Neutral
Apr 22, 2025

Animalcare Group PLC has announced a change in its voting rights structure due to an acquisition of shares by SEB Funds AB, a Swedish entity. This acquisition has resulted in SEB Funds AB holding 5.018261% of the voting rights in Animalcare, potentially impacting the company’s decision-making processes and shareholder dynamics.

Financial Disclosures
Animalcare Group to Announce 2024 Financial Results and Host Presentations
Neutral
Apr 16, 2025

Animalcare Group plc has announced that it will release its financial results for the year ended 31 December 2024 on 29 April 2025. The company will host virtual presentations for analysts and investors to discuss the results, with CEO Jenny Winter and CFO Chris Brewster leading the sessions. This announcement highlights Animalcare’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.